Telix Pharmaceuticals is trading at $10.94 (+4.05%) following a strong Q2 2026 update and positive guidance outlook.
- Quarterly revenue reached US$247 million, a 21% year-over-year increase, with management signaling that FY 2026 revenue is tracking toward the upper end of guidance.
- Positive investor sentiment is driven by FDA alignment on the ProstACT Global study, the Regeneron collaboration, and continued clinical pipeline progress.